Humanigen, Inc. (OTCQB: HGEN) is a biopharmaceutical company developing its portfolio of next-generation cell and gene therapies for the treatment of cancers via its novel, GM-CSF neutralization, and gene-knockout platforms. We welcome back Chairman & CEO of Humanigen, Cameron Durrant, MD, MBA, to explain the significance of “GM-CSF” pathway science for COVID-19 patients.